endofocusFOCUS ЭндокринологияFOCUS. Endocrinology2713-01772713-0185ООО "Издательство "Перо"10.62751/2713-0177-2024-5-3-05endofocus-118Research ArticleОБЗОР ЛИТЕРАТУРЫLITERATURE REVIEWРоль аналогов инсулина сверхбыстрого действия при сахарном диабетеThe role of superfast insulin analogues in diabetes mellitushttps://orcid.org/0000-0001-6385-540XДемидоваТ. Ю.DemidovaT. Yu.

Демидова Татьяна Юльевна – д.м.н., профессор, заведующая кафедрой эндокринологии ИКМ

г. Москва

Tatiana Yu. Demidova – D. Sci. (Med.), Prof.

Moscow

t.y.demidova@gmail.comhttps://orcid.org/0000-0001-6581-4521ГалстянГ. Р.GalstyanG. R.

Галстян Гагик Радикович – д.м.н., профессор

г. Москва

Gagik R. Galstyan – D. Sci. (Med.), Prof.

Moscow

galstyangagik964@gmail.comhttps://orcid.org/0000-0002-9430-0391ЛевицкаяА. Н.LevitskayaA. N.

Левицкая Анастасия Николаевна – ассистент кафедры эндокринологии ИКМ

г. Москва

Anastasiya N. Levitskaya – assistant at the Department of endocrinology

Moscow

levitskaya.anastasiya@internet.ruФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава РоссииPirogov Russian National Research Medical UniversityГНЦ РФ ФГБУ «Национальный медицинский исследовательский центр эндокринологии» Минздрава РоссииEndocrinology Research Centre202407112024533644Copyright © Демидова Т.Ю., Галстян Г.Р., Левицкая А.Н., 20242024Демидова Т.Ю., Галстян Г.Р., Левицкая А.Н.Demidova T.Y., Galstyan G.R., Levitskaya A.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://endofocus.elpub.ru/jour/article/view/118

В последние десятилетия значительные успехи в терапии сахарного диабета связаны с внедрением аналогов инсулина человека. Аналоги инсулина человека сверхбыстрого действия стали важным инструментом для достижения оптимального гликемического контроля и улучшения качества жизни пациентов. Благодаря своей уникальной фармакокинетике, эта группа препаратов обеспечивает более быстрое и предсказуемое начало действия инсулина, что позволяет максимально приблизить его профиль к секреции эндогенного инсулина. Ряд клинических испытаний подтвердили преимущество аналогов инсулина сверхбыстрого действия в контроле постпрандиальной гипергликемии по сравнению с препаратами инсулина предыдущего поколения.

In recent decades, significant advances in sugar therapy have been associated with the introduction of human insulin analogues. Superfast human insulin analogues have become an important tool for achieving optimal glycemic control and improving the quality of life of patients. Due to its unique pharmacokinetics, this group of insulin preparations provides a faster and more predictable onset of action, which allows its profile to be as close as possible to the secretion of endogenous insulin. A number of clinical trials have confirmed the advantage of superfast insulin analogues in the control of postprandial hyperglycemia compared with insulin preparations of the previous generation.

инсулинаналоги инсулина сверхбыстрого действиясахарный диабетпостпрандиальная гликемияinsulinsuperfast insulin analoguesdiabetes mellituspostprandial glycemiaReferencesGiorgino F, Battelino T, Bergenstal RM et al. The role of ultra-rapid-acting insulin analogs in diabetes: An Expert Consensus. J Diabetes Sci Technol. 2023: 19322968231204584. doi: 10.1177/19322968231204584.Giorgino F, Battelino T, Bergenstal RM et al. The role of ultra-rapid-acting insulin analogs in diabetes: An Expert Consensus. J Diabetes Sci Technol. 2023: 19322968231204584. doi: 10.1177/19322968231204584.Lind M, Catrina SB, Ekberg NR et al. Fast-acting insulin aspart in patients with type 1 diabetes in real-world clinical practice: A noninterventional, retrospective chart and database study. Diabetes Ther. 2023; 14(9): 1563–75. doi: 10.1007/s13300-023-01444-y.Lind M, Catrina SB, Ekberg NR et al. Fast-acting insulin aspart in patients with type 1 diabetes in real-world clinical practice: A noninterventional, retrospective chart and database study. Diabetes Ther. 2023; 14(9): 1563–75. doi: 10.1007/s13300-023-01444-y.Linnebjerg H, Zhang Q, LaBell E. et al. Pharmacokinetics and glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog® (Lispro) in younger adults and elderly patients with type 1 diabetes mellitus: A randomised controlled trial. Clin Pharmacokinet. 2020; 59(12): 1589–99. doi: 10.1007/s40262-020-00903-0.Linnebjerg H, Zhang Q, LaBell E. et al. Pharmacokinetics and glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog® (Lispro) in younger adults and elderly patients with type 1 diabetes mellitus: A randomised controlled trial. Clin Pharmacokinet. 2020; 59(12): 1589–99. doi: 10.1007/s40262-020-00903-0.Senior P, Hramiak I. Fast-acting insulin aspart and the need for new mealtime insulin analogues in adults with type 1 and type 2 diabetes: A Canadian perspective. Can J Diabetes. 2019; 43(7): 515–23. doi: 10.1016/j.jcjd.2019.01.004.Senior P, Hramiak I. Fast-acting insulin aspart and the need for new mealtime insulin analogues in adults with type 1 and type 2 diabetes: A Canadian perspective. Can J Diabetes. 2019; 43(7): 515–23. doi: 10.1016/j.jcjd.2019.01.004.Chan JCN, Lim LL, Wareham NJ et al. The Lancet Commission on diabetes: Using data to transform diabetes care and patient lives. Lancet. 2021; 396(10267): 2019–82. doi: 10.1016/S0140-6736(20)32374-6.Chan JCN, Lim LL, Wareham NJ et al. The Lancet Commission on diabetes: Using data to transform diabetes care and patient lives. Lancet. 2021; 396(10267): 2019–82. doi: 10.1016/S0140-6736(20)32374-6.Mathieu C, Gillard P, Benhalima K. Insulin analogues in type 1 diabetes mellitus: getting better all the time. Nat Rev Endocrinol. 2017; 13(7): 385–99. doi: 10.1038/nrendo.2017.39.Mathieu C, Gillard P, Benhalima K. Insulin analogues in type 1 diabetes mellitus: getting better all the time. Nat Rev Endocrinol. 2017; 13(7): 385–99. doi: 10.1038/nrendo.2017.39.Heise T, Piras de Oliveira C, Juneja R et al. What is the value of faster acting prandial insulin? Focus on Ultra Rapid Lispro. Diabetes Obes Metab. 2022; 24(9): 1689–701. doi: 10.1111/dom.14773.Heise T, Piras de Oliveira C, Juneja R et al. What is the value of faster acting prandial insulin? Focus on Ultra Rapid Lispro. Diabetes Obes Metab. 2022; 24(9): 1689–701. doi: 10.1111/dom.14773.Weiskorn J, Saboo B, Danne T. Current and future strategies in insulin development and treatment. Horm Res Paediatr. 2024: 1–9. doi: 10.1159/000540424.Weiskorn J, Saboo B, Danne T. Current and future strategies in insulin development and treatment. Horm Res Paediatr. 2024: 1–9. doi: 10.1159/000540424.Wong EY, Kroon L. Ultra-rapid-acting insulins: How fast is really needed? Clin Diabetes. 2021; 39(4): 415–23. doi: 10.2337/cd20-0119.Wong EY, Kroon L. Ultra-rapid-acting insulins: How fast is really needed? Clin Diabetes. 2021; 39(4): 415–23. doi: 10.2337/cd20-0119.Foster NC, Beck RW, Miller KM et al. State of type 1 diabetes management and outcomes from the T1D exchange in 2016–2018. Diabetes Technol Ther. 2019; 21(2): 66–72. doi: 10.1089/dia.2018.0384.Foster NC, Beck RW, Miller KM et al. State of type 1 diabetes management and outcomes from the T1D exchange in 2016–2018. Diabetes Technol Ther. 2019; 21(2): 66–72. doi: 10.1089/dia.2018.0384.McKnight JA, Wild SH, Lamb MJ et al. Glycaemic control of type 1 diabetes in clinical practice early in the 21st century: An international comparison. Diabet Med. 2015; 32(8): 1036–50. doi: 10.1111/dme.12676.McKnight JA, Wild SH, Lamb MJ et al. Glycaemic control of type 1 diabetes in clinical practice early in the 21st century: An international comparison. Diabet Med. 2015; 32(8): 1036–50. doi: 10.1111/dme.12676.Datye KA, Boyle CT, Simmons J et al. Timing of meal insulin and its relation to adherence to therapy in type 1 diabetes. J Diabetes Sci Technol. 2018; 12(2): 349–55. doi: 10.1177/1932296817728525.Datye KA, Boyle CT, Simmons J et al. Timing of meal insulin and its relation to adherence to therapy in type 1 diabetes. J Diabetes Sci Technol. 2018; 12(2): 349–55. doi: 10.1177/1932296817728525.Cengiz E, Danne T, Ahmad T et al. ISPAD clinical practice consensus guidelines 2022: insulin treatment in children and adolescents with diabetes. Pediatr Diabetes. 2022; 23(8): 1277–96. doi: 10.1111/pedi.13442.Cengiz E, Danne T, Ahmad T et al. ISPAD clinical practice consensus guidelines 2022: insulin treatment in children and adolescents with diabetes. Pediatr Diabetes. 2022; 23(8): 1277–96. doi: 10.1111/pedi.13442.Cengiz E, Bode B, Van Name M, Tamborlane WV. Moving toward the ideal insulin for insulin pumps. Expert Rev Med Devices. 2016; 13(1): 57–69. doi: 10.1586/17434440.2016.1109442.Cengiz E, Bode B, Van Name M, Tamborlane WV. Moving toward the ideal insulin for insulin pumps. Expert Rev Med Devices. 2016; 13(1): 57–69. doi: 10.1586/17434440.2016.1109442.van Bon AC, Bode BW, Sert-Langeron C et al. Insulin glulisine compared to insulin aspart and to insulin Lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes: A randomized controlled trial. Diabetes Technol Ther. 2011; 13(6): 607–14. doi: 10.1089/dia.2010.0224.van Bon AC, Bode BW, Sert-Langeron C et al. Insulin glulisine compared to insulin aspart and to insulin Lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes: A randomized controlled trial. Diabetes Technol Ther. 2011; 13(6): 607–14. doi: 10.1089/dia.2010.0224.Kordonouri O, Biester T, Weidemann J et al. Lipoatrophy in children, adolescents and adults with insulin pump treatment: Is there a beneficial effect of insulin glulisine. Pediatr Diabetes. 2020; 21(7): 1285–91. doi: 10.1111/pedi.13094.Kordonouri O, Biester T, Weidemann J et al. Lipoatrophy in children, adolescents and adults with insulin pump treatment: Is there a beneficial effect of insulin glulisine. Pediatr Diabetes. 2020; 21(7): 1285–91. doi: 10.1111/pedi.13094.Cheng R, Taleb N, Stainforth-Dubois M, Rabasa-Lhoret R. The promising future of insulin therapy in diabetes mellitus. Am J Physiol Endocrinol Metab. 2021; 320(5): E886–90. doi: 10.1152/ajpendo.00608.2020.Cheng R, Taleb N, Stainforth-Dubois M, Rabasa-Lhoret R. The promising future of insulin therapy in diabetes mellitus. Am J Physiol Endocrinol Metab. 2021; 320(5): E886–90. doi: 10.1152/ajpendo.00608.2020.Wilson LM, Castle JR. Recent advances in insulin therapy. Diabetes Technol Ther. 2020; 22(12): 929–36. doi: 10.1089/dia.2020.0065.Wilson LM, Castle JR. Recent advances in insulin therapy. Diabetes Technol Ther. 2020; 22(12): 929–36. doi: 10.1089/dia.2020.0065.Zhou J, Chen S, Cheng J et al. Ultra rapid lispro improves postprandial glucose control versus lispro in combination with insulin glargine/degludec in adults with type 2 diabetes: A prospective, randomized, double-blind, phase 3 trial. Sci Bull (Beijing). 2022; 67(17): 1785–91. doi: 10.1016/j.scib.2022.08.002.Zhou J, Chen S, Cheng J et al. Ultra rapid lispro improves postprandial glucose control versus lispro in combination with insulin glargine/degludec in adults with type 2 diabetes: A prospective, randomized, double-blind, phase 3 trial. Sci Bull (Beijing). 2022; 67(17): 1785–91. doi: 10.1016/j.scib.2022.08.002.Ma J, Yan X, Feng Q et al. Ultra-Rapid Lispro improved postprandial glucose control compared to insulin Lispro in predominantly Chinese patients with type 1 diabetes: A prospective, randomized, double-blind phase 3 study. Diabetes Obes Metab. 2024; 26(1): 311–18. doi: 10.1111/dom.15317.Ma J, Yan X, Feng Q et al. Ultra-Rapid Lispro improved postprandial glucose control compared to insulin Lispro in predominantly Chinese patients with type 1 diabetes: A prospective, randomized, double-blind phase 3 study. Diabetes Obes Metab. 2024; 26(1): 311–18. doi: 10.1111/dom.15317.Yuan L, Luo Y, Luo Y et al. Ultra Rapid Lispro improves postprandial glucose control versus lispro in combination with basal insulin: A study based on CGM in type 2 diabetes in China. Front Endocrinol (Lausanne). 2024; 15: 1364585. doi: 10.3389/fendo.2024.1364585.Yuan L, Luo Y, Luo Y et al. Ultra Rapid Lispro improves postprandial glucose control versus lispro in combination with basal insulin: A study based on CGM in type 2 diabetes in China. Front Endocrinol (Lausanne). 2024; 15: 1364585. doi: 10.3389/fendo.2024.1364585.Leohr J, Kazda C, Liu R et al. Ultra-Rapid Lispro shows faster pharmacokinetics and reduces postprandial glucose excursions versus Humalog® in patients with type 2 diabetes mellitus in a randomized, controlled crossover meal test early phase study. Diabetes Obes Metab. 2022; 24(2): 187–95. doi: 10.1111/dom.14561.Leohr J, Kazda C, Liu R et al. Ultra-Rapid Lispro shows faster pharmacokinetics and reduces postprandial glucose excursions versus Humalog® in patients with type 2 diabetes mellitus in a randomized, controlled crossover meal test early phase study. Diabetes Obes Metab. 2022; 24(2): 187–95. doi: 10.1111/dom.14561.Kazda C, Leohr J, Liu R et al. Ultra Rapid Lispro (URLi) shows accelerated pharmacokinetics and greater reduction in postprandial glucose versus Humalog® in patients with type 1 diabetes mellitus in a randomized, double-blind meal test early-phase study. Diabetes Obes Metab. 2022; 24(2): 196–203. doi:10.1111/dom.14563Kazda C, Leohr J, Liu R et al. Ultra Rapid Lispro (URLi) shows accelerated pharmacokinetics and greater reduction in postprandial glucose versus Humalog® in patients with type 1 diabetes mellitus in a randomized, double-blind meal test early-phase study. Diabetes Obes Metab. 2022; 24(2): 196–203. doi:10.1111/dom.14563Dutta D, Nagendra L, Bhattacharya S, Sharma M. Efficacy and safety of Ultra-Rapid Lispro insulin in managing type-1 and type-2 diabetes: A systematic review and meta-analysis. Indian J Endocrinol Metab. 2023; 27(6): 467–75. doi: 10.4103/ijem.ijem_225_23.Dutta D, Nagendra L, Bhattacharya S, Sharma M. Efficacy and safety of Ultra-Rapid Lispro insulin in managing type-1 and type-2 diabetes: A systematic review and meta-analysis. Indian J Endocrinol Metab. 2023; 27(6): 467–75. doi: 10.4103/ijem.ijem_225_23.Klaff L, Cao D, Dellva MA et al. Ultra Rapid Lispro improves postprandial glucose control compared with Lispro in patients with type 1 diabetes: Results from the 26-week PRONTO-T1D study. Diabetes Obes Metab. 2020; 22(10): 1799–807. doi: 10.1111/dom.14100.Klaff L, Cao D, Dellva MA et al. Ultra Rapid Lispro improves postprandial glucose control compared with Lispro in patients with type 1 diabetes: Results from the 26-week PRONTO-T1D study. Diabetes Obes Metab. 2020; 22(10): 1799–807. doi: 10.1111/dom.14100.Warren M, Bode B, Cho JI et al. Improved postprandial glucose control with Ultra Rapid Lispro versus Lispro with continuous subcutaneous insulin infusion in type 1 diabetes: PRONTO-Pump-2. Diabetes Obes Metab. 2021; 23(7): 1552–61. doi: 10.1111/dom.14368.Warren M, Bode B, Cho JI et al. Improved postprandial glucose control with Ultra Rapid Lispro versus Lispro with continuous subcutaneous insulin infusion in type 1 diabetes: PRONTO-Pump-2. Diabetes Obes Metab. 2021; 23(7): 1552–61. doi: 10.1111/dom.14368.Miura J, Imori M, Nishiyama H, Imaoka T. Ultra-Rapid Lispro efficacy and safety compared to Humalog® in Japanese patients with type 1 diabetes: PRONTO-T1D subpopulation analysis. Diabetes Ther. 2020; 11(9): 2089–104. doi: 10.1007/s13300-020-00892-0.Miura J, Imori M, Nishiyama H, Imaoka T. Ultra-Rapid Lispro efficacy and safety compared to Humalog® in Japanese patients with type 1 diabetes: PRONTO-T1D subpopulation analysis. Diabetes Ther. 2020; 11(9): 2089–104. doi: 10.1007/s13300-020-00892-0.Blevins T, Zhang Q, Frias JP et al.; PRONTO-T2D Investigators. Randomized double-blind clinical trial comparing Ultra Rapid Lispro with Lispro in a basal-bolus regimen in patients with type 2 diabetes: PRONTO-T2D. Diabetes Care. 2020; 43(12): 2991–98. doi: 10.2337/dc19-2550.Blevins T, Zhang Q, Frias JP et al.; PRONTO-T2D Investigators. Randomized double-blind clinical trial comparing Ultra Rapid Lispro with Lispro in a basal-bolus regimen in patients with type 2 diabetes: PRONTO-T2D. Diabetes Care. 2020; 43(12): 2991–98. doi: 10.2337/dc19-2550.Aronson R, Biester T, Leohr J et al. Ultra rapid lispro showed greater reduction in postprandial glucose versus Humalog in children, adolescents and adults with type 1 diabetes mellitus. Diabetes Obes Metab. 2023; 25(7): 1964–72. doi: 10.1111/dom.15063.Aronson R, Biester T, Leohr J et al. Ultra rapid lispro showed greater reduction in postprandial glucose versus Humalog in children, adolescents and adults with type 1 diabetes mellitus. Diabetes Obes Metab. 2023; 25(7): 1964–72. doi: 10.1111/dom.15063.Leohr J, Dellva MA, Carter K et al. Ultra Rapid Lispro (URLi) accelerates insulin Lispro absorption and insulin action vs Humalog® consistently across study populations: A pooled analysis of pharmacokinetic and glucodynamic data. Clin Pharmacokinet. 2021; 60(11): 1423–34. doi: 10.1007/s40262-021-01030-0.Leohr J, Dellva MA, Carter K et al. Ultra Rapid Lispro (URLi) accelerates insulin Lispro absorption and insulin action vs Humalog® consistently across study populations: A pooled analysis of pharmacokinetic and glucodynamic data. Clin Pharmacokinet. 2021; 60(11): 1423–34. doi: 10.1007/s40262-021-01030-0.Heise T, Linnebjerg H, Coutant D et al. Ultra rapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogues: A phase 1 randomized, crossover study. Diabetes Obes Metab. 2020; 22(10): 1789–98. doi: 10.1111/dom.14094.Heise T, Linnebjerg H, Coutant D et al. Ultra rapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogues: A phase 1 randomized, crossover study. Diabetes Obes Metab. 2020; 22(10): 1789–98. doi: 10.1111/dom.14094.Mathieu C, Bode BW, Franek E et al. Efficacy and safety of fast-acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52-week, randomized, treat-to-target, phase III trial. Diabetes Obes Metab. 2018; 20(5): 1148–55. doi: 10.1111/dom.13205.Mathieu C, Bode BW, Franek E et al. Efficacy and safety of fast-acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52-week, randomized, treat-to-target, phase III trial. Diabetes Obes Metab. 2018; 20(5): 1148–55. doi: 10.1111/dom.13205.Носков С.М., Кокшарова Е.О., Арефьева А.Н. с соавт. Первый биоаналог инсулина лизпро сверхбыстрого действия: результаты двойного слепого рандомизированного клэмписследования. Медицинский совет. 2024; 18(13): 174–180. doi: 10.21518/ms2024-345.Носков С.М., Кокшарова Е.О., Арефьева А.Н. с соавт. Первый биоаналог инсулина лизпро сверхбыстрого действия: результаты двойного слепого рандомизированного клэмписследования. Медицинский совет. 2024; 18(13): 174–180. doi: 10.21518/ms2024-345.Саверская Е.Н., Кокшарова Е.О., Носков С.М. с соавт. Результаты оценки биоподобия препаратов инсулина аспарт отечественного и зарубежного производства с использованием метода гиперинсулинемического эугликемического клэмпа и исследования применения нового сверхбыстродействующего отечественного биосимиляра в помпах. Медицинский совет. 2024;1 8(1): 135–142. doi: 10.21518/ms2024-023.Саверская Е.Н., Кокшарова Е.О., Носков С.М. с соавт. Результаты оценки биоподобия препаратов инсулина аспарт отечественного и зарубежного производства с использованием метода гиперинсулинемического эугликемического клэмпа и исследования применения нового сверхбыстродействующего отечественного биосимиляра в помпах. Медицинский совет. 2024;1 8(1): 135–142. doi: 10.21518/ms2024-023.

The authors declare that there are no conflicts of interest present.